JPWO2023032955A5 - - Google Patents

Info

Publication number
JPWO2023032955A5
JPWO2023032955A5 JP2023545587A JP2023545587A JPWO2023032955A5 JP WO2023032955 A5 JPWO2023032955 A5 JP WO2023032955A5 JP 2023545587 A JP2023545587 A JP 2023545587A JP 2023545587 A JP2023545587 A JP 2023545587A JP WO2023032955 A5 JPWO2023032955 A5 JP WO2023032955A5
Authority
JP
Japan
Prior art keywords
acid sequence
amino acid
seq
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023545587A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023032955A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2022/032523 external-priority patent/WO2023032955A1/ja
Publication of JPWO2023032955A1 publication Critical patent/JPWO2023032955A1/ja
Publication of JPWO2023032955A5 publication Critical patent/JPWO2023032955A5/ja
Pending legal-status Critical Current

Links

JP2023545587A 2021-08-31 2022-08-30 Pending JPWO2023032955A1 (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021140932 2021-08-31
PCT/JP2022/032523 WO2023032955A1 (ja) 2021-08-31 2022-08-30 抗成長ホルモン抗体

Publications (2)

Publication Number Publication Date
JPWO2023032955A1 JPWO2023032955A1 (https=) 2023-03-09
JPWO2023032955A5 true JPWO2023032955A5 (https=) 2025-09-02

Family

ID=85411222

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023545587A Pending JPWO2023032955A1 (https=) 2021-08-31 2022-08-30

Country Status (6)

Country Link
US (1) US20240391996A1 (https=)
EP (1) EP4397762A4 (https=)
JP (1) JPWO2023032955A1 (https=)
CN (1) CN117881784A (https=)
TW (1) TW202323289A (https=)
WO (1) WO2023032955A1 (https=)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US7264963B1 (en) 1995-08-18 2007-09-04 Morphosys Ag Protein(poly)peptide libraries
US5945296A (en) * 1996-03-29 1999-08-31 Pharmacia & Upjohn Ab Monoclonal antibody
SE9601231D0 (sv) * 1996-03-29 1996-03-29 Pharmacia Ab Monoclonal antibody
JPH10191974A (ja) * 1997-01-16 1998-07-28 Mitsui Chem Inc ヒト成長ホルモンに特異的に反応するモノクローナル抗体
ES2327382T3 (es) 1999-07-20 2009-10-29 Morphosys Ag Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro.
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn

Similar Documents

Publication Publication Date Title
US20230242651A1 (en) Stable antibody variable domain framework combinations
JP2023539245A5 (https=)
AU2022241522B2 (en) Bispecific antibody to a-syn/igf1r and use thereof
JP2023509448A5 (https=)
US20250282879A1 (en) Multispecific antibodies having specificity for il-4r and il-31
RU2013115927A (ru) АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ
JP2013507115A5 (https=)
JP2021530244A5 (https=)
US11365240B2 (en) Anti-HSA antibodies
JP2022523507A5 (https=)
JP2024105229A5 (https=)
RU2014123030A (ru) Антагонистические антитела против человеческого рецептора гормона роста и способы их применения
JP2024515560A5 (https=)
JP2022500455A5 (https=)
JP2022531552A5 (https=)
JP2025506341A5 (https=)
JPWO2023032955A5 (https=)
US20250388665A1 (en) Anti-tnf-alpha antibodies and compositions
JP2023548471A5 (https=)
JP2023512827A5 (https=)
JPWO2021162098A5 (https=)
US20260098100A1 (en) Il-4r and tslp inhibitors and methods of use thereof
US20250154242A1 (en) Anti-tnf-alpha antibodies and compositions
EP4019090A1 (en) Antibody variable domains that bind il-4r
WO2024038095A1 (en) NOVEL ANTI-RGMb ANTIBODIES